Taken together, our study identifies CBS as a novel regulator of AIS maintenance and a potential tumor suppressor in gastric cancer pathogenesis, potentially providing a new metabolic vulnerability that can be harnessed to target PI3K/AKT/mTORC1-driven cancers. Here, CBS is linked to gastric cancer.